Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 201–300 of 913
Glial Dysfunction in Parkin Null Mice: Effects of Aging
Solano, R. M., Casarejos, M. J., Menéndez-Cuervo, J., Rodriguez-Navarro, J. A., García de Yébenes, J., & Mena, M. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4609-07.2008 · Cited by 117
“Parkin knock-out (PK-KO) mice are used to investigate the role of parkin (Goldberg et al., 2003; Itier et al., 2003; Von Coelln et al., 2004; Perez and Palmiter, 2005).”
BackgroundPhosphorylation of Parkin at serine 65 is essential for its activation in vivo
McWilliams, T. G., Barini, E., Pohjolan-Pirhonen, R., Brooks, S. P., Singh, F., Burel, S., Balk, K., Kumar, A., Montava-Garriga, L., Prescott, A. R., et al. (2018) · Open Biology · doi:10.1098/rsob.180108 · Cited by 116
Parkin and relatives: the RBR family of ubiquitin ligases
Marín, I., Lucas‐Lledó, J. I., Gradilla, A., & Ferrús, A. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00226.2003 · Cited by 137
“Parkin mutant mice were described as almost normal, just exhibiting some anomalies in dopamine release and in behavioral tests (25, 37).”
BackgroundShen, J., & Cookson, M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.012 · Cited by 124
“Given that PINK1 has a mitochondrial targeting sequence, it is reasonable to expect that fails to reproduce the selective loss of dopaminergic neurons seen in human patients (Goldberg et al., 2003;its physiological substrates may include mitochondrial proteins.”
BackgroundSelf-citationOmura, T., Kaneko, M., Okuma, Y., Matsubara, K., & Nomura, Y. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/239854 · Cited by 113
Springer, W., Hoppe, T., Schmidt, E., & Baumeister, R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi371 · Cited by 112
Setsuie, R., Wang, Y.-L., Mochizuki, H., Osaka, H., Hayakawa, H., Ichihara, N., Li, H., Furuta, A., Sano, Y., Sun, Y., et al. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.015 · Cited by 131
Chandran, J. S., Lin, X. Z., Zapata, A. G., Höke, A., Shimoji, M., Moore, S. O., Galloway, M. P., Laird, F. M., Wong, P. C., Price, D. L., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.011 · Cited by 127
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B
Tran, T. A., Nguyen, A. D., Chang, J., Goldberg, M. S., Lee, J.-K., & Tansey, M. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023660 · Cited by 112
“generated as previously described [18] and have been backcrossed”
MethodSelf-citationNon‐motor behavioural impairments in parkin‐deficient mice
Zhu, X., Maskri, L., Herold, C., Bader, V., Stichel, C. C., Güntürkün, O., & Lübbert, H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05812.x · Cited by 112
Parkinson’s disease: experimental models and reality
Jiang, P., & Dickson, D. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 111
“A number of parkin knockout mice have been reported; however, none of them has SN dopamine-related motor deficits, but mild reduction in DA without neuron loss has been observed in some models [66, 123, 153, 213].”
Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond
Bayne, A. N., & Trempe, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03203-4 · Cited by 130
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
“Parkin knockout mice do not show loss of dopamine neurons in the SNc and have increased levels of extracellular dopamine in the striatum (Goldberg et al., 2003).”
BackgroundAn emerging role of PARK2 in cancer
Xu, L., Lin, D., Yin, D., & Koeffler, H. P. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1107-0 · Cited by 120
Mitochondria: A Therapeutic Target for Parkinson’s Disease?
Luo, Y., Hoffer, A., Hoffer, B., & Qi, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920704 · Cited by 110
“disturbance Absent [72,73]”
Yang, D., Ying, J., Wang, X., Zhao, T., Yoon, S., Yang, F., Zheng, Q., Liu, X., Yu, W., & Hua, F. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.654785 · Cited by 132
Parkin is required for exercise-induced mitophagy in muscle: Impact of aging
Chen, C. C. W., Erlich, A. T., Crilly, M. J., & Hood, D. A. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2017 · Cited by 108
Functional models of Parkinson's disease: A valuable tool in the development of novel therapies
Jenner, P. (2009) · Annals of Neurology · doi:10.1002/ana.21489 · Cited by 107
“Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alphasynuclein(1-120): implications for Lewy body disorders.”
BackgroundSong, P., Li, S., Wu, H., Gao, R., Rao, G., Wang, D., Chen, Z., Ma, B., Wang, H., Sui, N., et al. (2016) · Protein & Cell · doi:10.1007/s13238-015-0230-9 · Cited by 107
“…we wondered that parkin may be involved in selectively degradation of Mfn1/2 and Drp1 in STR and SN regions and thus further compared the protein levels of a number of mitochondrial and autophagy markers in wild-type and germline parkin exon 3 knockout mice (parkin −/− ) (Goldberg et al., 2003).”
InfluentialAgarwal, S., & Muqit, M. M. K. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.09.005 · Cited by 110
Parkinsonism genes: culprits and clues
Abeliovich, A., & Flint Beal, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04102.x · Cited by 107
The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease
Tufekci, K. U., Genc, S., & Genc, K. (2011) · Parkinson's Disease · doi:10.4061/2011/487450 · Cited by 107
Animal Models of Parkinson's Disease: A Gateway to Therapeutics?
Le, W., Sayana, P., & Jankovic, J. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0234-1 · Cited by 134
“They may have increased extracellular striatal DA, reduced synaptic excitability in striatal mediumsized spiny neurons, and typical progressive sensorimotor and behavioral impairments that are typically seen in disorders with demonstrated pathologies in the nigrostriatal pathway[85].”
BackgroundPINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis
Sarraf, S. A., Sideris, D. P., Γιαγτζόγλου, Ν., Ni, L., Kankel, M. W., Sen, A., Bochicchio, L. A., Huang, C.-H., Nussenzweig, S. C., Worley, S. H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.085 · Cited by 118
“Parkin-KO mice are viable, with no overt phenotypes, neurodegeneration, or reduced lifespan (Goldberg et al., 2003).”
BackgroundFleming, S. M., Salcedo, J. D., Hutson, C. B., Rockenstein, E. M., Masliah, E., Levine, M. S., & Chesselet, M.-F. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.005 · Cited by 118
“…DA content in the striatum have been observed in the Thy1-aSyn mice used in this study (Maidment et al., 2006) as well as in parkin knockout mice (Goldberg et al., 2003) and DJ-1 knockout mice (Chen et al., 2005), indicating a provocative common feature of mice expressing diverse PD-related…”
BackgroundMethodSelf-citationDrosophila as a Model to Study Mitochondrial Dysfunction in Parkinson's Disease
Guo, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009944 · Cited by 105
Agirre, X., Román‐Gómez, J., Vázquez, I., Jiménez‐Velasco, A., Garate, L., Montiel‐Duarte, C., Artieda, P., Cordeu, L., Lahortiga, I., Calasanz, M. J., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21584 · Cited by 104
Jeong, H.-K., Jou, I., & Joe, E.-H. (2010) · Experimental and Molecular Medicine · doi:10.3858/emm.2010.42.12.085 · Cited by 103
Quality Control in Neurons: Mitophagy and Other Selective Autophagy Mechanisms
Evans, C. S., & Holzbaur, E. L. F. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.06.031 · Cited by 110
“Interplay of neuronal mitophagy pathways and mitochondrial quality control—The mild phenotypes displayed in PINK1 and Parkin KO mice in vivo, suggest other mitochondrial mechanisms may be at play [63, 65, 67, 68].”
BackgroundInfluentialMetabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 112
Kubli, D. A., Cortez, M. Q., Moyzis, A. G., Najor, R. H., Lee, Y., & Gustafsson, Å. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130707 · Cited by 102
“129S4-Park2/J, stock number 006582) and have been described previously [17, 25].”
Kim, J.-H., Choi, D.-J., Jeong, H.-K., Kim, J., Kim, D. W., Choi, S. Y., Park, S.-M., Suh, Y. H., Jou, I., & Joe, E.-H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.007 · Cited by 102
Knockout mouse models of sperm flagellum anomalies
Escalier, D. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml013 · Cited by 116
“Mice lacking parkin are fertile (Goldberg et al., 2003; Itier et al., 2003).”
Bornhorst, J., Chakraborty, S., Meyer, S., Lohren, H., Richter-Brockmann, S., Knight, A. L., Caldwell, K. A., Caldwell, G. A., Kärst, U., Schwerdtle, T., et al. (2013) · Metallomics · doi:10.1039/c3mt00325f · Cited by 108
Wang, C., Kang, X., Zhou, L., Chai, Z., Wu, Q., Huang, R., Xu, H., Hu, M., Sun, X., Sun, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02593-y · Cited by 111
“Control virus Control virus (30) (29) (18) (17) ** ** Syt11 OE Syt11 OE”
Zhou, H., Falkenburger, B. H., Schulz, J. B., Tieu, K., Xu, Z., & Xia, X. G. (2007) · International Journal of Biological Sciences · doi:10.7150/ijbs.3.242 · Cited by 99
“Deletion of either the Parkin or DJ-1 genes by gene knockout approach does not cause dopaminergic neuron death [43-49].”
BackgroundNeuronal pathology in Parkinson?s disease
Schulz, J. B. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-1081-0 · Cited by 102
“Similarly, the number of SNpc dopaminergic neurons does not decline in parkin-deficient mice (Goldberg et al. 2003; Itier et al. 2003).”
BackgroundHatano, T., Kubo, S., Sato, S., & Hattori, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06403.x · Cited by 120
Human disorders of ubiquitination and proteasomal degradation
Jiang, Y.-H., & Beaudet, A. L. (2004) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000133634.79661.cd · Cited by 98
The emerging roles of protein homeostasis‐governing pathways in Alzheimer's disease
Cheng, J., North, B. J., Zhang, T., Dai, X., Tao, K., Guo, J., & Wei, W. (2018) · Aging Cell · doi:10.1111/acel.12801 · Cited by 97
“In contrast to apoptosis, necrosis is a rapid cellular reaction without programmed procedures, which makes it more difficult to control or reverse by therapeutic intervention (Gorman, 2008; Nikolova, Roos, Krämer, Strik, & Kaina, 2017).”
BackgroundMarazziti, D., Golini, E., Mandillo, S., Magrelli, A., Witke, W., Matteoni, R., & Tocchini‐Valentini, G. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403661101 · Cited by 107
Inflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Role of ubiquitin–proteasome-mediated proteolysis in nervous system disease
Hegde, A. N., & Upadhya, S. C. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.07.006 · Cited by 96
Wang, H.-B., Loh, D. H., Whittaker, D. S., Cutler, T., Howland, D., & Colwell, C. S. (2018) · eneuro · doi:10.1523/eneuro.0431-17.2017 · Cited by 95
“The challenging beam test is a modified version of the beam traversal test first described by Goldberg and colleagues (Goldberg et al., 2003), and was used to characterize the motor deficits of Q175 mutant mice in previous studies (Loh et al., 2013, Wang et al., 2017).”
MethodIntegral UBL domain proteins: a family of proteasome interacting proteins
Hartmann‐Petersen, R., & Gordon, C. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2003.12.006 · Cited by 106
Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease
Trancikova, A. K., Tsika, E., & Moore, D. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4200 · Cited by 100
“While parkin KO mice fail to recapitulate key aspects of PD pathology (58, 71, 188), they do reproduce some mitochondrial phenotypes that are also evident in Drosophila parkin models (Table 4).”
Genetic Mouse Models of Huntington’s Disease: Focus on Electrophysiological Mechanisms
Cepeda, C., Cummings, D. M., André, V. M., Holley, S. M., & Levine, M. S. (2010) · ASN Neuro · doi:10.1042/an20090058 · Cited by 93
“For example, most genetic mouse models of Parkinson’s disease have been unable to reproduce significant loss of DA cells even though functional changes occur (Goldberg et al., 2003; Itier et al., 2003; Kitada et al., 2009; Watson et al., 2009; Wu et al., 2009).”
BackgroundSelf-citationDeletion of the Parkin coregulated gene causes male sterility in the quaking viable mouse mutant
Lorenzetti, D., Bishop, C. E., & Justice, M. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401832101 · Cited by 93
New Developments in Genetic rat models of Parkinson's Disease
Creed, R. B., & Goldberg, M. S. (2018) · Movement Disorders · doi:10.1002/mds.27296 · Cited by 103
Self-citationToxin-Induced and Genetic Animal Models of Parkinson's Disease
Hisahara, S., & Shimohama, S. (2011) · Parkinson's Disease · doi:10.4061/2011/951709 · Cited by 91
Parkin is a disease modifier in the mutant SOD 1 mouse model of ALS
Palomo, G. M., Granatiero, V., Kawamata, H., Konrad, C., Kim, M., Arreguin, A. J., Zhao, D., Milner, T. A., & Manfredi, G. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201808888 · Cited by 91
“We utilized the constitutive PKO mouse, because it does not present overt neurodegenerative phenotypes (Goldberg et al , 2003; Kitada et al , 2009), possibly due to compensatory mechanisms (Dawson et al , 2010).”
Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice
Noda, S., Sato, S., Fukuda, T., Tada, N., Uchiyama, Y., Tanaka, K., & Hattori, N. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104717 · Cited by 100
Mitochondrial Behavior in Axon Degeneration and Regeneration
Wang, B., Huang, M., Shang, D., Yan, X., Zhao, B., & Zhang, X. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.650038 · Cited by 115
“Mutations in Parkin impair Complex I activity, mitochondrial fusion, and the plasticity of synapses (Goldberg et al., 2003).”
Backgroundder Perren, A. V., Toelen, J., Carlon, M. S., den Haute, C. V., Coun, F., Heeman, B., Reumers, V., Vandenberghe, L. H., Wilson, J. M., Debyser, Z., et al. (2011) · Gene Therapy · doi:10.1038/gt.2010.179 · Cited by 97
Genetics of parkin-linked disease
West, A. B., & Maidment, N. T. (2004) · Human Genetics · doi:10.1007/s00439-003-1074-6 · Cited by 97
Self-citationGiguère, N., Delignat-Lavaud, B., Herborg, F., Voisin, A., Li, Y., Jacquemet, V., Anand-Srivastava, M., Gether, U., Giros, B., & Trudeau, L.-É. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008352 · Cited by 89
Experimental models of Parkinson's disease: Challenges and Opportunities
Lal, R., Singh, A., watts, S., & Chopra, K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176819 · Cited by 95
A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin
Omura, T., Kaneko, M., Okuma, Y., Orba, Y., Nagashima, K., Takahashi, R., Fujitani, N., Matsumura, S., Hata, A., Kubota, K., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04155.x · Cited by 98
Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?
Cummins, N., & Götz, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2692-9 · Cited by 92
Matsuda, N., & Tanaka, K. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1231 · Cited by 88
“…although the accumulation of α Sp22 in parkin-deficient PD brains has been shown [43], Ko and Goldberg reported the lack of α Sp22 accumulation in the brains of AR-JP patients and parkin-deficient mice [54,56], suggesting that the significance of α Sp22 as a parkin substrate might be still obscure.”
Davison, E. J., Pennington, K., Hung, C., Peng, J., Rafiq, R., Ostareck‐Lederer, A., Ostareck, D. H., Ardley, H. C., Banks, R. E., & Robinson, P. A. (2009) · PROTEOMICS · doi:10.1002/pmic.200900126 · Cited by 88
Autophagy as a Cellular Stress Response Mechanism in the Nervous System
Peker, N., & Gözüaçık, D. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.017 · Cited by 87
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
“2A, n = 5) but not parkin mice generated on the same background [40] (Fig.”
BackgroundRetractedNeuronal pathology in Parkinson?s disease
Schulz, J. B., & Falkenburger, B. H. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0954-y · Cited by 127
RetractedRodent models for dystonia research: Characteristics, evaluation, and utility
Jinnah, H. A., Hess, E. J., LeDoux, M. S., Sharma, N., Baxter, M. G., & DeLong, M. R. (2005) · Movement Disorders · doi:10.1002/mds.20364 · Cited by 88
Human DJ-1-specific Transcriptional Activation of Tyrosine Hydroxylase Gene
Ishikawa, S., Taira, T., Takahashi-Niki, K., Niki, T., Ariga, H., & Iguchi‐Ariga, S. M. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137034 · Cited by 97
Mitochondrial dynamics, cell death and the pathogenesis of Parkinson’s disease
Büeler, H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0465-0 · Cited by 95
“Ablation of Parkin in mice resulted in respiratory defects, reduced expression of subunits of respiratory complexes I and IV, decreased levels of anti-oxidant proteins, increased protein and lipid peroxidation [115], and abnormalities in dopamine neurotransmission, but no loss of dopaminergic neurons [116, 117].”
Bogaerts, V., Theuns, J., & Van Broeckhoven, C. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 86
“Parkin knockout mice had normal numbers of DAergic neurons, but displayed subtle deficits in behaviour and DAergic neurotransmission (Goldberg et al. 2003; Itier et al. 2003).”
BackgroundInteraction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
Madsen, D. A., Schmidt, S. I., Blaabjerg, M., & Meyer, M. (2021) · Cells · doi:10.3390/cells10020283 · Cited by 92
Mortality, oxidative stress and tau accumulation during ageing in parkin null mice
Rodríguez‐Navarro, J. A., Casarejos, M. J., Menéndez, J., Solano, R. M., Rodal, I., Gómez, A., Yébenes, J. G. D., & Mena, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04762.x · Cited by 84
Parkin Protects against Mitochondrial Toxins and β-Amyloid Accumulation in Skeletal Muscle Cells
Rosen, K. M., Veereshwarayya, V., Moussa, C. E.-H., Fu, Q., Goldberg, M. S., Schlossmacher, M. G., Shen, J., & Querfurth, H. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512649200 · Cited by 84
Self-citationYamaguchi, O., Murakawa, T., Nishida, K., & Otsu, K. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.03.010 · Cited by 84
“Furthermore, Parkin-deficient mice show mild phenotypes, which exhibit grossly normal brain morphology [86], indicating that there may be unknown mechanisms of mitophagy in mammalian cells other than the PINK1/Parkin axis.”
Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neuron s
Zheng, L., Bernard-Marissal, N., Moullan, N., D’Amico, D., Auwerx, J., Moore, D. J., Knott, G., Aebischer, P., & Schneider, B. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw418 · Cited by 84
Molecular Insights into Parkinson's Disease
Rochet, J., Hay, B. A., & Guo, M. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00011-4 · Cited by 96
Progress in the pathogenesis and genetics of Parkinson's disease
Mizuno, Y., Hattori, N., Kubo, S., Sato, S., Nishioka, K., Hatano, T., Tomiyama, H., Funayama, M., Machida, Y., & Mochizuki, H. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.2273 · Cited by 107
Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
Mounsey, R. B., & Teismann, P. (2011) · Parkinson's Disease · doi:10.4061/2011/617472 · Cited by 81
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease
Kamienieva, I., Duszyński, J., & Szczepanowska, J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-020-00229-8 · Cited by 87
“They exhibit normal general appearance, behaviour [163] and longevity [165, 166] and have normal brain morphology [163, 164].”
BackgroundMethodInfluentialNeuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson’s Disease?
Barnum, C. J., & Tansey, M. G. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0283-6 · Cited by 85
Cell Death Pathways in Parkinson's Disease: Role of Mitochondria
Yao, Z., & Wood, N. W. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2624 · Cited by 80
“Intriguingly, although a mild nonprogressive motor deficit, reduced synaptic excitability, and increased striatal extracellular dopamine concentrations were reported in young parkin knockout mice (49, 61); no loss of DAergic neurons or inclusion formations were described.”
Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration
Meka, D. P., Müller-Rischart, A. K., Nidadavolu, P., Mohammadi, B., Motori, E., Ponna, S. K., Aboutalebi, H., Bassal, M. A., Annamneedi, A., Finckh, B., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79300 · Cited by 87
Parkinson’s disease mouse models in translational research
Antony, P. M. A., Diederich, N. J., & Balling, R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9330-x · Cited by 91
“However, none of these models shows a progressive loss of nigrostriatal dopaminergic neurons (Goldberg et al. 2003; Itier et al. 2003; Martella et al. 2009; Palacino et al. 2004; Periquet et al. 2005; Rodriguez-Navarro et al. 2007; Stichel et al. 2007; Von Coelln et al. 2004; Zhu et al. 2007).”
BackgroundGiovannone, B., Tsiaras, W. G., de la Monte, S., Klysik, J., Lautier, C., Karashchuk, G., Goldwurm, S., & Smith, R. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp430 · Cited by 78
“For example, disruption of the Parkin or DJ-1 genes in mice results in neurodegeneration and motor function deficits, but these animals do not have cellular deficits in the nigrostriatal dopaminergic pathway (27-29).”
BackgroundTargeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
“Oxidative stress markers have been observed in SN specimens in many PD studies.”
BackgroundNew pathogenic insights from large animal models of neurodegenerative diseases
Yin, P., Li, S., Li, X., & Yang, W. (2022) · Protein & Cell · doi:10.1007/s13238-022-00912-8 · Cited by 83
“protecting against mitochondrial damage, did not produce any obvious degeneration either in the mouse brain (Goldberg et al., 2003; Perez and Palmiter, 2005; Kitada et al., 2009).”
BackgroundAbnormal Mitochondrial Quality Control in Neurodegenerative Diseases
Yan, X., Wang, B., Hu, Y., Wang, S., & Zhang, X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00138 · Cited by 79
“Because of the lack of in vivo phenotypes in PINK1 and Parkin mutant mice, it is hard to evaluate the impact of PINK1/Parkin-mediated mitophagy deficiency on PD pathology in vivo (Goldberg et al., 2003; Perez and Palmiter, 2005; Kitada et al., 2009).”
BackgroundUpregulation of Parkin in Endophilin Mutant Mice
Cao, M., Milosevic, I., Giovedi, S., & De Camilli, P. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1710-14.2014 · Cited by 75
“However, Parkin KO mice are grossly normal, without any obvious neurodegenerative sign (e.g., loss of dopaminergic neurons; Goldberg et al., 2003) and expression levels of endophilin and several other endocytic proteins in Parkin KO newborn brains were not different from controls (data not shown;…”
Parkinson’s disease: a rethink of rodent models
Melrose, H. L., Lincoln, S. J., Tyndall, G. M., & Farrer, M. J. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0461-3 · Cited by 74
“Several groups have also described spontaneous and targeted knockout of the Parkin gene in mice (Goldberg et al. 2003; Itier et al. 2003; Lorenzetti et al. 2004; Von Coelln et al. 2004; Perez and Palmiter 2005).”
BackgroundInfluentialmiR-103a-3p regulates mitophagy in Parkinson’s disease through Parkin/Ambra1 signaling
Zhou, J., Zhao, Y., Li, Z., Zhu, M., Wang, Z., Li, Y., Xu, T., Feng, D., Zhang, S., Tang, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105197 · Cited by 78
Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice
Yamaguchi, H., & Shen, J. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-10 · Cited by 74
“These results are consistent with our prior report showing that loss of parkin function alone in mice is also insufficient to cause loss of DA neurons up to the age of 2 years [40].”
ResultSelf-citationThe cellular basis of dendrite pathology in neurodegenerative diseases
Kweon, J. H., Kim, S., & Lee, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.1.131 · Cited by 73
“Consistent with this, it has been observed that the animal models of neurodegenerative diseases, such as HD (4) and PD (5, 6), displayed behavioral”
BackgroundMitochondrial proteomics in free radical research
Bailey, S. M., Landar, A. L., & Darley-Usmar, V. M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.10.011 · Cited by 78
Parkin and defective ubiquitination in Parkinson's disease.
Dawson, T. M. (2006) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-211-45295-0_32 · Cited by 81
“Moreover, several animal models deficient in parkin have been developed and none of the parkin substrates appear to accumulate in parkin-null mice (Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005; Von Coelln et al., 2004b).”
BackgroundCommon anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells
Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P. H., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.124 · Cited by 79
Ubiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies
Lim, K.-L. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.769 · Cited by 71
The ubiquitin–proteasome system and neurodegenerative disorders
Layfield, R., Lowe, J. S., & Bedford, L. (2005) · Essays in Biochemistry · doi:10.1042/eb0410157 · Cited by 78
Cannon, J. R., Geghman, K. D., Tapias, V., Sew, T., Dail, M. K., Li, C., & Greenamyre, J. T. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.11.007 · Cited by 72
Alpha‐synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway
Wu, N., Joshi, P. R., Cepeda, C., Masliah, E., & Levine, M. S. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22327 · Cited by 72
“In agreement with our previous study in parkin KO mice, there is decreased excitation of MSSNs (Goldberg et al., 2003).”
BackgroundResultInfluentialSelf-citationParkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting
Williams, E. T., Glauser, L., Tsika, E., Jiang, H., Islam, S., & Moore, D. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy224 · Cited by 72
Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome
Mulherkar, S. A., & Jana, N. R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.002 · Cited by 71
Genetically engineered mouse models of Parkinson's disease
Crabtree, D. M., & Zhang, J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.019 · Cited by 70
“Parkin is an E3 ubiquitin ligase and mutations in the gene are the most common cause of juvenile Parkinsonism; however, the corresponding mouse models with Parkin deficiency showed only a mild or no phenotype without any loss of dopaminergic neurons [68;69].”
Background
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.